Drugs / Upifitimab rilsodotin
Upifitimab rilsodotin
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05329545 | Jun 2022 → Sep 2023 | fallopian tube cancer, ovarian serous adenocarcinoma, primary peritoneal carcinoma | Mersana Therapeutics | Terminated | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Upifitimab rilsodotin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05329545 ↗ |
| Known as | upifitamab rilsodotin | “UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion...” NCT05329545 ↗ |
| Known as | XMT-1536 | “UP-NEXT is a double-blind, randomized, placebo-controlled study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion...” NCT05329545 ↗ |
| Modality | Other / unclassified | “antibody-drug conjugate (ADC)” NCT05329545 ↗ |
| Route | Intravenous | “administered as an intravenous infusion” NCT05329545 ↗ |